Bullous pemphigoid associated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: A case series of 13 patients
- Author(s)
- Yun, JSW; Chan, OB; Goh, M; McCormack, CJ;
- Details
- Publication Year 2023-02,Volume 64,Issue #1,Page 131-137
- Journal Title
- Australasian Journal of Dermatology
- Publication Type
- Case report
- Abstract
- We present a case series of 13 patients, the first Australian single-centre study of bullous pemphigoid (BP) associated with immune checkpoint inhibitors (ICI): cytotoxic T-lymphocyte antigen (CTLA4) and programmed cell death receptor (PD1) inhibitors. All our patients achieved adequate control of BP with a combination of treatments including oral prednisolone, intravenous immunoglobulin, rituximab and omalizumab. The majority of patients ceased or interrupted immunotherapy treatment upon diagnosis of BP and greater tumour progression was seen in the cohort who ceased immunotherapy.
- Publisher
- Wiley
- Keywords
- Humans; Australia; B7-H1 Antigen/drug effects; Cell Death; *Pemphigoid, Bullous/etiology/pathology; *Immune Checkpoint Inhibitors/adverse effects/therapeutic use; bullous pemphigoid; immune check point inhibitor; immune-related adverse events; immunotherapy
- Department(s)
- Surgical Oncology
- PubMed ID
- 36514287
- Publisher's Version
- https://doi.org/10.1111/ajd.13960
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-06-15 07:25:01
Last Modified: 2023-06-15 07:25:48